Lunai Bioworks Inc.

Lunai Bioworks Inc. operates through three subsidiaries: Renovaro Biosciences, Renovaro Cube, and BioSymetrics. Renovaro Cube refers to GediCube Intl. Ltd. and its wholly owned subsidiaries GediCube, B.V. and Grace Systems B.V., which were acquired on February 13, 2024. BioSymetrics refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025. Renovaro Biosciences is a biotechnology company that aims to develop advanced allogeneic cell and gene therapies. These therapies are intended to promote stronger immune system responses, potentially leading to long-term or life-long cancer remission in some of the deadliest cancers, provided the necessary funding is obtained. Following the acquisition of GEDi Cube Intl on February 13, 2024, the Company's primary focus and resources have shifted to developing GEDi Cube Intl technologies, emphasizing molecular diagnostics and oncology. Renovaro Biosciences seeks to train the immune system to help individuals fight diseases more effectively through allogeneic cell and/or gene therapy. The company aims to leverage general principles and advances in immune response knowledge to engineer cells with enhanced attributes to promote the recognition and elimination of disease cells. The strategic benefit of allogeneic cell therapy technologies is the potential to manufacture large, "off-the-shelf" banks of therapeutic cells. These cells would be readily available on demand for healthcare professionals, potentially decreasing the time between diagnosis and treatment. In certain treatments, such as for cancer, cells from healthy donors are engineered to introduce signaling molecules designed to enhance specific immune cells' ability to recognize diseased cells and help recruit other cells to destroy cancer or virus-infected cells.